Expression in Escherichia coli, purification and characterization of heparinase I from Flavobacterium heparinum

被引:60
作者
Ernst, S
Venkataraman, G
Winkler, S
Godavarti, R
Langer, R
Cooney, CL
Sasisekharan, R
机构
[1] MIT, DEPT CHEM ENGN, CAMBRIDGE, MA 02139 USA
[2] MIT, HARVARD MIT DIV HLTH SCI & TECHNOL, CAMBRIDGE, MA 02139 USA
关键词
D O I
10.1042/bj3150589
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The use of heparin for extracorporeal therapies has been problematical due to haemorrhagic complications; as a consequence, heparinase I from Flavobacterium heparimum is used for the determination of plasma heparin and for elimination of heparin from circulation. Here we report the expression of recombinant heparinase I in Escherichia coli, purification to homogeneity and characterization of the purified enzyme. Heparinase I was expressed with an N-terminal histidine tag. The enzyme was insoluble and inactive, but could be refolded, and was purified to homogeneity by nickel-chelate chromatography. The cumulative yield was 43 %, and the recovery of purified heparinase I was 14.4 mg/l of culture, The N-terminal sequence and the molecular mass as analysed by matrix-assisted laser desorption MS were consistent with predictions from the heparinase I gene structure. The reverse-phase HPLC profile of the tryptic digest, the Michaelis-Menten constant K-m (47 mu g/ml) and the specific activity (117 units/mg) of purified recombinant heparinase I were similar to those of the native enzyme. Degradation of heparin by heparinase I results in a characteristic product distribution, which is different from those obtained by degradation with heparinase II or III from F. heparimum. We developed a rapid anion-exchange HPLC method to separate the products of enzymic heparin degradation, using POROS perfusion chromatography media. Separation of characteristic di-, tetra- and hexasaccharide products is performed in 10 min. These methods for the expression, purification and analysis of recombinant heparinase I may facilitate further development of heparinase I-based medical therapies as well as further investigation of the structures of heparin and heparan sulphate and their role in the extracellular matrix.
引用
收藏
页码:589 / 597
页数:9
相关论文
共 64 条
  • [1] Abildgaard U., 1989, HEPARIN CHEM BIOL PR, P495
  • [2] HEPARINASE IN THE ACTIVATED CLOTTING TIME ASSAY - MONITORING HEPARIN-INDEPENDENT ALTERATIONS IN COAGULATION FUNCTION
    BAUGH, RF
    DEEMAR, KA
    ZIMMERMANN, JJ
    [J]. ANESTHESIA AND ANALGESIA, 1992, 74 (02) : 201 - 205
  • [3] BERNSTEIN H, 1988, METHOD ENZYMOL, V137, P515
  • [4] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
  • [5] Comper W.D, 1981, HEPARIN RELATED POLY
  • [6] SUBSTRATE-SPECIFICITY OF THE HEPARIN LYASES FROM FLAVOBACTERIUM-HEPARINUM
    DESAI, UR
    WANG, HM
    LINHARDT, RJ
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1993, 306 (02) : 461 - 468
  • [7] DIETRICH CP, 1973, J BIOL CHEM, V248, P6108
  • [8] ANALYSIS OF GLYCOPROTEIN-ASSOCIATED OLIGOSACCHARIDES
    DWEK, RA
    EDGE, CJ
    HARVEY, DJ
    WORMALD, MR
    PAREKH, RB
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1993, 62 : 65 - 100
  • [9] ENZYMATIC DEGRADATION OF GLYCOSAMINOGLYCANS
    ERNST, S
    LANGER, R
    COONEY, CL
    SASISEKHARAN, R
    [J]. CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1995, 30 (05) : 387 - 444
  • [10] BIOREACTOR BASED ON SUSPENDED PARTICLES OF IMMOBILIZED ENZYME
    FREED, LE
    VUNJAKNOVAKOVIC, GV
    DRINKER, PA
    LANGER, R
    [J]. ANNALS OF BIOMEDICAL ENGINEERING, 1993, 21 (01) : 57 - 65